LeMaitre Vascular Inc (LMAT)
78.88
+0.11
(+0.14%)
USD |
NASDAQ |
May 31, 16:00
78.89
+0.01
(+0.01%)
After-Hours: 20:00
LeMaitre Vascular Research and Development Expense (Annual): 16.97M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.97M |
| December 31, 2022 | 13.29M |
| December 31, 2021 | 11.80M |
| December 31, 2020 | 10.10M |
| December 31, 2019 | 9.276M |
| December 31, 2018 | 8.197M |
| December 31, 2017 | 6.636M |
| December 31, 2016 | 6.141M |
| December 31, 2015 | 5.479M |
| December 31, 2014 | 4.671M |
| December 31, 2013 | 5.243M |
| December 31, 2012 | 5.092M |
| Date | Value |
|---|---|
| December 31, 2011 | 4.425M |
| December 31, 2010 | 5.488M |
| December 31, 2009 | 5.91M |
| December 31, 2008 | 5.328M |
| December 31, 2007 | 4.591M |
| December 31, 2006 | 3.301M |
| December 31, 2005 | 3.015M |
| December 31, 2004 | 2.12M |
| December 31, 2003 | |
| December 31, 2002 | 1.295M |
| December 31, 2001 | 0.862M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
9.276M
Minimum
2019
16.97M
Maximum
2023
12.29M
Average
11.80M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Baxter International Inc | 667.00M |
| AtriCure Inc | 73.92M |
| Becton Dickinson & Co | 1.237B |
| Perspective Therapeutics Inc | 21.31M |
| Xtant Medical Holdings Inc | 1.336M |